May 15 |
PaxMedica files Nasdaq delisting appeal notice
|
May 15 |
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
|
May 7 |
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
|
Apr 26 |
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
|
Apr 23 |
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
|
Apr 16 |
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
|
Apr 12 |
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
|
Apr 11 |
PaxMedica shares soar 125% post-market on drug update
|
Apr 11 |
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
|
Mar 13 |
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
|